Improving CAR-T therapies for Acute Myeloid Leukemia
Official title: Engineering best in class Acute Myeloid Leukemia (AML) CAR-T therapies by enhancing persistence and defining the immune landscape of AML
Funded at University of California, San Francisco · NIH-10998336 · Data updated 2026-11-12
This study is working on a new type of treatment for people with Acute Myeloid Leukemia (AML) to make it safer and more effective, so patients can have a better chance of recovery and less risk of the cancer coming back.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | December 17, 2024 |
| Project end | December 16, 2027 |
| Funding year | 2024 |
| Award (this year) | $41,380 |
| NIH project number | 1F31CA294978-01 |
| Project ID | NIH-10998336 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Acute Myeloid Leukemia who have not responded well to existing therapies.
✕Less likely to help
Patients with other types of leukemia or those who are not diagnosed with Acute Myeloid Leukemia may not benefit from this research.
What this research studies
This research focuses on enhancing CAR-T cell therapies specifically for patients with Acute Myeloid Leukemia (AML), a type of blood cancer with low survival rates. The project aims to address challenges such as the lack of specific antigens for AML and the toxicities associated with current treatments. By developing a new cellular therapy platform, the research seeks to improve T-cell persistence and reduce the risk of relapse. Patients may benefit from a more effective and targeted treatment option that could lead to better outcomes.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with Acute Myeloid Leukemia, potentially improving survival rates.
How similar studies have gone: Other research has shown promise in enhancing CAR-T therapies for blood cancers, but this specific approach for AML is relatively novel.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Rampersaud, Sham — University of California, San Francisco
- Study coordinator: Rampersaud, Sham
Related research
Other NIH-funded projects on the same topics.
-
Acute Myeloid Leukemia: Improving Targeted Therapies through Genetically Defined PDX Models
Researchers are using patient-like leukemia models to develop therapies that target specific genetic features of AML to improve survival.
-
A broader genomic risk picture to guide AML treatment
AIM to refine how genetic information guides treatment decisions for adults with acute myeloid leukemia by looking at how inherited and recurrent mutations affect risk.
-
RNA Polymerase II as a Therapeutic Target in AML with RAS Activation
This project explores a new way to treat a common type of blood cancer (AML) by blocking a key machinery (RNA Polymerase II) that cancer cells use when the RAS signaling pathway is overactive.
-
SHP2 and BCL2 inhibitors together for AML growth and resistance
A patient-focused look at whether combining SHP2 inhibitors with a BCL2 inhibitor can slow or stop AML, especially in people whose disease has FLT3 or KIT mutations.
-
Targeting RNA polymerase II in AML with RAS pathway activation
This project tests drugs that block RNA polymerase II to help people whose acute myeloid leukemia has RAS pathway activation and is resistant to FLT3 inhibitors.
-
New treatment approach for myelodysplastic syndrome and acute myeloid leukemia
This project aims to develop a new antibody-based therapy to help people with MDS or AML, especially older or frail patients who cannot tolerate high-dose chemotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.